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Abstract
In this paper, a parametrization strategy based on reduced order methods is presented
for tumor growth PDE models. This is applied to a new simple spatial model for lung
metastasis including angiogenesis. The goal is to help clinicians monitoring tumors and
eventually predicting their evolution or response to a particular kind of treatment. To
illustrate the whole approach, a clinical case including the natural history of the lesion,
the response to a chemotherapy, and the relapse before a radiofrequency ablation is
presented.




Themetastatic disease to the lung is frequently encountered in patients with cancer what-
ever the primary location, and it has been associated with poor prognosis. The incidence
of such disease in patients who have died of an extrathoracic malignancy is reported to be
of 20% to 54% [1]. Nevertheless, limited pulmonary metastatic disease can now be suc-
cessfully treated not only for palliative reasons. By controlling the primary tumor and in
the absence of widely disseminated disease in many organs, the resection or the ablation
of pulmonary metastases may prolong survival, improve the quality of life, and, in some
cases, ensure cure [2]. During the last decade, a better management of the metastatic dis-
ease to the lung has been achieved by the evolution of imaging, medical oncology, and
surgical techniques. There has been improvements in CT imaging quality and scan time
[3], as well as advances in the field of nuclear medicine and MRI [4] which can give more
precise information on the location and extent of the disease. In particular, there has been
widespread use of PET/CT for evaluating patients with metastatic pulmonary disease,
which can early detect metabolically active metastatic disease [5]. The targeted oncology
treatments can achieve improved responsiveness, and the resection of the lesion turns
to be possible now with minimally invasive surgical techniques as well as percutaneous
thermal ablations (see [6-8]). In order to continue this trend and to improve the knowl-
edge of the pulmonary metastatic disease, some authors advocated the development of
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new tools able to explore the first steps of metastatic implantation [9]. The majority of
pulmonary metastases are derived from cancer cells that enter the lungs through the pul-
monary arteries and disperse in alveolar capillaries. More rarely, metastatic disease is the
consequence of lymphatic spreading or development directly in the bronchial tree (see
[10]). Most of these cancer cells are able to adhere to the endothelium of the capillar-
ies. However, the cell survival is ultimately determined by local and oncology factors.
Althoughmost of these malignant cells do not survive [2], those that survive penetrate the
endothelium of the capillaries and install in the pulmonary parenchyma, where they grow.
Therefore, a better understanding of this tumor growth could widely have direct clinical
applications. Cancer growth modeling aims at describing, understanding, and predict-
ing the evolution of tumors using numerical models. This science is constantly evolving,
from the first cellular automata adapted to the microscopic scale to ordinary differential
equations describing the global dynamics of the tumor or partial differential equations
taking the spatial distribution of the cancer cells into account. If modeling can be used
to help biologists understand the complex mechanisms of tumor growth, in this work,
the motivation is to develop a tool for clinical oncologists to improve patient monitoring
and eventually to predict the response to a treatment of some metastases to the lung. As
we deal with medical images, the spatial information is important and partial differential
equations seem to be the most adapted method to model tumor growth in our context. A
true difficulty is to include in a model the biological interactions, as complex as they are,
responsible for the tumor evolution without neglecting that the model must be relevant
for in vivo applications, and its parameters need to be recovered from clinical images.
Among the diversity of PDE models existing on this topic, we chose, as a starting point,
the one developed in [11] for the promising results obtained. The diffusion term for nutri-
ent is replaced by a micro model of angiogenesis (see [12]) which seems more relevant at
the medical imaging scale. The goal is to simulate the evolution of a tumor from a given
patient so we had to define a calibration method to personalize the model. This method
must be a good trade-off between accuracy and computation time. For that purpose, the
approach chosen is based on a reduced order method named proper orthogonal decom-
position (POD) (see [13] or [14]). The way we address this problem is similar to that of
[11]: we first design a PDE model of tumor growth dealing with the spatial distribution
of cancer cells with respect to time T(t, x, y). This PDE model contains some parameters
that are patient specific. The problem is therefore to determine for which parameters the
numerical solution fits the data. Once these parameters have been estimated (we call this
step the calibration of the model), one can perform a prediction for a longer time scale.
The outline of this paper is the following: in the following paragraph, we present a clin-
ical case of a single metastasis including natural growth, response to a treatment, and
relapse. The ‘Methods’ section is devoted to the presentation of the PDE model of tumor
growth that we use and the data assimilation technics. Then, the results are discussed in
a dedicated part.
A typical clinical case
In this paper, we will focus on a clinical case of a patient with an isolated metastasis in the
lung from a primary bladder tumor. The history of the patient is presented in Figure 1.
Figure 1a,b,c shows the CT scans of the natural history of the lesion, i.e. without treat-
ment. The patient has been seen for a radiofrequency ablation on 2008/12/10. At this
Jouganous et al. Journal of Computational Surgery  (2015) 2:1 Page 3 of 17
Figure 1 Extract from a sequence of CT scans showing the evolution of a nodule (a to f).
point, the lesion was too large and the oncologist started a chemotherapy. Figure 1d,e
shows the CT scans during the treatment while Figure 1f shows the relapse a month after
the end of the chemotherapy. A radiofrequency ablation was performed in July 2009. The
questions that we want to answer in this paper are the following ones:
1. Is it possible with Figure 1a,b to estimate Figure 1c?
2. Is it possible with Figure 1a,b,c,d to estimate the efficacy of the treatment Figure 1e
and the amount of the relapse Figure 1f?
Methods
Amathematical model for lungmetastasis
The model we use in this work is derived from the one described in [11]. We here con-
sider only one kind of cancer cells. The tumor micro environment, and in particular the
amount of nutrients available, is essential to explain its evolution. Consequently, instead
of directly modeling the nutrient density, we use a very simplified angiogenesis model
to take into account the process by which the tumor escapes the avascular stage. The
biological hypotheses of the model are the following:
• One single type of nutrient is considered. Its concentration controls cellular
proliferation and death.
• The amount of nutrients available is proportional to the quantity of blood vessels in
the tissue. The nutrient diffusion is not taken into account as it is not relevant at the
scale we consider.
• The only cellular motion we take into account is the passive transport due to volume
variations caused by mitosis or cellular death.
• Cancer cells are continuously switching from the proliferative to the quiescent
phenotype.
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Cell behavior
The tumor cell density is denoted by T and satisfies the following equation:
∂T
∂t + ∇ · (vT) = (γp − γd)T , (1)
where v is the transport velocity. The left part of this transport equation satisfies the
mass conservation principle, and the source term drives this evolution (proliferation and
death) of the cells population. The coefficients for proliferation and death by hypoxia
(lack of dioxygen), γp and γd, are detailed in Equations 2 and 3. Above a given threshold
of nutrient supplyMth, cancer cells tend to proliferate whereas below this threshold, they
starve to death. The use of a hyperbolic tangent in both γp and γd expressions amounts to
smoothing and regularizing the threshold functions, and K is a smoothing constant fixed.
These functions are given by:
γp(M) = γ0 1 + tanh(K(M − Mth))2 , (2)
γd(M) = γ1 1 − tanh(K(M − Mth))2 . (3)
From the tumor cells density T and the field γp, we can have an insight on the prolifer-
ative and quiescent cells location. Indeed, the cells that are proliferative were γp = γ0 and
quiescent elsewhere, so proliferative cells are given by the expression P = γp
γ0
T whereas





T . In addition to cancer cells, we also take
into account the healthy tissue whose density is denoted by S. We assume here that this
healthy tissue is transported at the same velocity as the cancer cells but is globally nei-
ther proliferating nor dying. More precisely, cellular birth and death counterbalance each
other at the timescales we consider so we have, for S, a transport equation without source
term (Equation 4):
∂S
∂t + ∇ · (vS) = 0. (4)
As we consider that the tissue is saturated, the sum of the two densities T and S is equal
to 1 which gives the value of S (Equation 5) (see [15]):
S = 1 − T . (5)
Summing Equations 1 and 4, we obtain an equation on v (6):
∇ · v = (γp − γd)T . (6)
This is not sufficient to determine the velocity. However, to close the system of
equations (see [16]), we consider that the velocity v is obtained using a Darcy law in
Equation 7: v is derived from a pressure or potential π in the tissue.
v = −∇π . (7)
This formulation amounts to saying that tumor cells are pushed out if they are prolifer-
ating or pulled in if they are dying. Here, we could also use a Stokes equation to describe
the velocity (see [15]) but it complicates the model without improving significantly its
accuracy or biological relevance.
Angiogenesis
At the end of the avascular stage of its development, the tumor reaches such a size that
its direct environment is not able to supply enough nutrients to allow the tumor to keep
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on growing. At this point, cancer cells emit chemical signals such as vascular endothelial
growth factor (VEGF) which result in the emergence of a tumoral neovasculature (see
[12,17,18]). Research on this phenomenon is very active in particular to develop anti-
angiogenic treatments. As most of the metastases visible on medical imaging are in the
vascular stage, it was important to take the angiogenesis process into account. However,
it is out of reach to model this extremely complex phenomenon in details. We therefore
choose to use a very compact model in order to achieve a good balance between the
complexity of the model and the feasibility of the data assimilation (see next section). It
is described by the last two equations Equations 8 and 9. The scalar variable ξ is the total


















Tdω − λξ . (8)
As we assume that the quantity of nutrient is proportional to the density of blood ves-
sels in the tissue, we mixed these two notions in the unique variable M we shall call
‘vasculature’. It can be seen as the environment ability to meet the needs of the tumor in
term of nutrients and could be related with the carrying capacity introduced in the Hah-
nfeldt ODE model [19]. The vasculatureM is damaged by proliferating tumor cells while
angiogenesis is promoted by quiescent cells; it therefore obeys
∂M






The model takes into account some important mechanisms involved in tumor growth
such as proliferation, death, or angiogenesis. Moreover, it is simpler than the previous
one [11] as we just have one sort of cancer cells and there is no transport or diffusion of
the vasculature. This trade-off is made to keep the model biologically relevant yet simple
enough to be parametrized.
Taking therapeutical effects into account
The model architecture makes easy to include different types of treatment. Chemother-
apy effects can be simulated by adding a death term on Equation 1 as −δT . In this case,
Equation 1 becomes:
∂T
∂t + ∇ · (vT) = (γp − γd)T − δT . (10)
To fullfill the saturation assumption, Equation 6 is modified as follows:
∇ · v = (γp − γd − δ)T . (11)
We can also take into account an anti-angiogenic drug. In this case, we define a




< 1 under treatment.
If we consider that it inhibits the production of pro-angiogenic agent, Equation 8 can
be modified as follows:
∂ξ







Tdω − λξ .
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If the anti-angiogenic drug also inhibits the growth factor membrane receptors on the
endothelial cells, we can add a corresponding term to the vasculature equation 9:
∂M






We postpone the modeling of this effect of anti-angiogenic drugs to a future work.
Data assimilation technique
The idea is to use the model that has been described in the previous section to obtain
a forecast of the evolution of the lung tumor presented in the ‘Background’. This model
contains numerous parameters that have to be recovered using the two images in order
to perform the prediction. Some appear explicitly in the equations, such as the scalars α,
β , γ0, γ1, η, λ, andMth. Others are implicit and imposed as initial conditions, such as the
scalar field M(t = 0) and the scalar ξ(t = 0), and in the case where the patient is under
treatment, at least one additional parameter has to be determined. The goal of this section
is to build a calibration method fast and accurate enough to recover an adequate set of
parameters describing the tumor evolution.
Simplifying assumptions
As mentioned before, we have eight scalars and one spatial field to identify. These
quantities cannot be estimated by in vitro or in vivo experiments. Furthermore, the
parameterization problem is ill posed. We can fix ξ(t = 0) arbitrarily without loss of gen-
erality since the variations of ξ(t = 0) can be taken into account with parameters α, β ,
and λ. For convenience, concerning the order of magnitude in our numerical code, we
take ξ(t = 0) = 0.1. ForM, the situation is more complex and we have no universal solu-
tion to propose. We choose to takeM(t = 0) = 0.8×T +S. This means that the available
quantity of nutrients is lower inside the lesion than outside and that initially these quan-
tities are constant. Note that this property is not satisfied for t > 0 because of Equation 9.
This is one of the strengths of the model: it is possible to obtain an heterogeneous dis-
tribution of nutrients within the tumor during the evolution that accounts for complex
evolution and that makes the difference with scalar models dealing only with the volume
of the tumor. Again, the ratio 0.8 in the initialization ofM is arbitrary and has to be related
toMth and K .
Sensitivity analysis
In order to restrict the parameter space, we perform a sensitivity analysis on the model.
It aims at determining if some parameters have more influence on the results than oth-
ers. In this case, it means that the variation ranges of the less meaningful parameters
must be modified or that we can simply fix them to a nominal value. For each parameter
(pi)i=1...7 = (α,β , γ0, γ1, λ, η,Mth), we choose a range of variation [ai; bi] given in Table 1.
Denoting by T (t, x, y, p1, . . . , p7), the solution given by the PDE system described previ-





tf , x, y, p1, . . . , p7
)
dxdy for each i = 1 to 7, tf being
the final time.We evaluate the mean valuemi and the standard deviation Si of these quan-
tities when the values of the parameters (pi)i=1...7 are uniformly distributed on [ai; bi]. We
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use Morris method (see [20]) to perform this computation. The corresponding values of
(mi, Si) are plotted in Figure 2.
The influence of the parameter can be established by the distance to the origin of the
corresponding point (mi, Si). In our case, we can see that the most influent parameter is
γ0 which is not surprising as it rules the exponential growth of the tumor. Conversely,
the model is almost not sensitive to variations of α and β in the ranges we consider so a
part of the inverse problem can be simplified by fixing them thus reducing the degrees of
freedom.
Formulation of the inverse problem
Given a sequence ofmedical images or snapshots of the tumor, we aim at finding a suitable
set of parameters able to reproduce the observed behavior. In other words, simulations
with this set must fit as well as possible the clinical data. For this, our approach is to use a
scalar objective function, which basically quantifies the distance between the observable
data and themodel simulation, and try tominimize it. There are different ways tomeasure
Figure 2 Sensitivity analysis on the tumor growth model using the Morris method. Effect of each
parameter on the final tumor volume. The farther the point is from the origin, the more meaningful the
corresponding parameter is for the model.
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this distance, and as a criterion, we chose a combination of the comparison of the mass
and the L2 distance as follows. The cost function is denoted by fobj:













Tdata(ti, x, y)dxdy −
∫






where (p1, . . . , pk) is the parameter set used in the model simulation, w1 and w2 are
weights to balance the influence of each term, and ns is the number of snapshots we have.
The first term in the objective function accounts for the shape while the second one only
accounts for its volume. Of course, as initial data for our simulation, we use the ‘exact’
value given by the data at time t = t1, therefore the sum starts at i = 2. As a consequence,
we need at least two images of the metastasis at different times to personalize the model.
The tumor cell density Tdata(ti) is extracted from the ith snapshot (corresponding to time
ti). The quantity Tmodel(ti, p1, . . . , pk) is the tumor cell density given by the simulation at
time ti and for the parameters (p1, . . . , pk). To compute the L2 distance, a data registra-
tion is necessary. We simply translate the images in order that their centers of mass match
with the center of mass of the first image T0. The masses are computed by integrating the
density on the domain. From a computational point of view, whatever the minimization
method is, one has to evaluate many times the objective function. It implies to simulate
the model for lots of parameter sets which could be quite expensive. For instance, if we
use a gradient algorithm to estimate seven parameters, at each iteration, the model is sim-
ulated eight times. To make the calibration faster, we have developed a strategy based on
a reduced order method called proper orthogonal decomposition (POD) (see [21]).
Building a reduced ordermodel to speed up computations
POD resolutionmethod for infinite dynamical systems consists in approaching partial dif-
ferential equation systems with ordinary differential equations by decoupling the time and
space variables (see [13] and [14]). The initial infinite dimension problem is replaced by
a finite dimension (the smallest as possible) problem. Let us first describe the POD used
on the tumor cell density variable T . As we want to decouple space and time variables, we




aTi (t)Ti (X) + (X, t),
where aTi are scalar functions depending on time and Ti are spatial functions called
modes and represent the geometry of the variable T . The dimension of the reduced prob-
lem is denoted by d. As it is an approximation, an error (t,X) is committed. The goal of
POD is to provide us the best basis of spatial functions Ti to minimize the error.
These functionsTi are extracted from a database of admissible behaviors of T . To gener-
ate this database, we sample the parameter space, run the direct model for each parameter




k of the variable T . If the sample is cor-
rectly chosen, we have a representative set of geometrical configurations for the tumor
cell density. Then, we look for the functions Ti in the d-dimensional vectorial space
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approximation space). These functions are taken as an orthonormal basis verifying:
∀h ∈ {1, . . . , d}, ||T(X, t) −
h∑
i=1






This property is very interesting as it allows us to use a small number of modes without
loosing too much accuracy. The basis solution to this minimization problem is extracted













by the formula (Equation 13):





vTi [k] STk , (13)
where λTi denotes the ith eigenvalue ofMT and vTi [k] the kth component of the ith eigen-
vector ofMT .
Once we have obtained these POD modes, we compute the projection of the PDE system
on the approximation space Eh using the eigenmodes Ti (X). We use the POD approach
on both the tumor cell density T and the pressure field π which are the two fields driven
by PDEs in our system. Thus, we obtain the approximations T(X, t) = ∑nTi=1 aTi (t)Ti (X)
and π(X, t) = ∑nπi=1 aπi (t)πi (X), nT and nπ being the numbers of modes we use to
represent T and π .
Reduced order model on T: We inject the POD expression of T in Equation 1, where





















k , which gives:


























solved with an implicit Euler scheme:














That can be rewritten as:
dAT











Therefore, we avoid the time interpolation phase that was essential in [11] to approxi-
mate the time derivative. Consequently, the hypothesis that two consecutive medical data
are close in time is not necessary in our case and the accuracy of the scheme is improved.
Reduced order model on π : From Equations 7 and 6, we obtain:
−π = T .
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aπj πj = T .












= (T |πi ) . (15)
Here again, the system above can be written in the compact form:

















i). These values are obtained by projecting the initial configurations of










Resolution of the inverse problem
The aim of this section is to sum up the algorithm we use in order to solve the inverse
problem associated to the cost function (Equation 12), that is, find (p1, . . . , p7) =
argmin(fobj(p1, . . . , p7)). We proceed in two steps.
Step 1: We perform a Monte Carlo method in order to determine a first approximation
of the parameters and to avoid a local minimizer. This consists in comparing simulations
performed with parameter sets randomly chosen in an empirical parameter space. We
keep the parameters set corresponding to the lower value of the cost function fobj (see
Equation 12).
Step 2: Once we have this first approximation, we start a gradient descent method using
the result of the first step as initialization. In this second step, the value of parameters
α and β are fixed to those obtained in step 1, since the sensitivity analysis performed in
paragraph 4.2 shows a low variability of the results with respect to their values.
Note that the use of the POD method implies that we deal with the evaluation of solu-




The method previously described was applied to our clinical case (Figure 1). The first
scan (on 2008/06/07) represents the initial condition for the tumor cell density T . The
other one (on 2008/09/22) is used in the objective function from Equation 12 as Tdata.
The process to extract information from this type of medical images is quite simple. First,
the tumor is delineated by a radiologist. The scan measures the permeability to X-rays
which we assume is proportional to the density of cells. So we consider that the tumor cell
density T is proportional to the normalized intensity of the corresponding voxel on the
image. To further simplify the problem, we assume, as a first approximation, that tumor
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cells do not die from hypoxia so we fix γ1 = 0. Let us remind that we also set the initial
conditions for M and ξ . We still have six parameters to estimate. A parameter space is
empirically defined, and we generate a database of simulations on this space. In this case,
the database contains 374 simulations; and for each simulation, we save 5 snapshots for
both T and π . From this collection of snapshots, we extract the POD modes and the
calibration process is launched with the reduced model. For the simulation of the POD
model, we only use 36 modes on T and 10 on π which is here a good balance between
accuracy and computation speed. We obtain the set of parameters given in Table 2.
These parameters are used to make a simulation on the direct model and try to predict
the evolution of the tumor. A third CT scan on 2008/12/10 is available to compare our
prediction and the real evolution.
The result of this simulation is compared with the observed growth of the metastasis in
Figure 3. The prediction from the model is satisfactory. To have a quantitative criterion
of evaluation of the prediction, we can consider the mass of the tumor which is drawn in
Figure 4.
We can see that the horizontal error of prediction of the third scan is less than 10
days. Moreover, the relative error is below 5% of the total duration which is lower than
the 10% segmentation error made by the clinician. If we look at the curves, we observe
a small difference between the reduced model simulation and the direct model sim-
ulation. This is due to the POD hypothesis and the truncation of the POD basis. To
quantify the accuracy in shape of the simulation, we calculated spatial indicators as the
DICE and the volume concordance given by: DICE = 100 × 2 ∗ |Tmodel
⋂
Tdata|
|Tmodel| + |Tdata| and
VC = 100 ×
(
1 − |Tmodel − Tdata||Tdata|
)
. Moreover, the temporal prediction error is another
significant indicator. Indeed, clinicians often need to know when the tumor will reach a
critical size. It could be, for instance, the size over which the tumor cannot be treated
using radiofrequencies. We denote by ti the time of the ith exam and t′i the time when the
simulated tumor reaches the size of the real tumor at the ith exam. It is relevant to look
at the delay between the simulation and the real case ti − t′i and the normalized delay
100 × ti−t′iti−t0 , i = 1, 2. The values at the calibration time point (2008/09/22) and the final
scan (2008/12/10) are given on Table 3.
Chemotherapy
Given the fast growth of this metastasis, clinicians decided to treat the patient with a
chemotherapy. The treatment starts just after the last scan on 2008/12/10 and ends on
2009/06/29. To monitor the efficiency of the treatment, three control scans were planned:
two during the treatment (on 2009/03/21 and 2009/05/27) and a last one, 1 month after
Table 2 Parameter set obtained by the inverse problem
α Angiogenic agent synthesis factor 8.109
β Angiogenic growth factor 7.241
η Vasculature destruction factor 0.673
γ0 Proliferation rate 1.116
γ1 Death by hypoxia rate 0
λ Angiogenic agent destruction rate 0.865
Mth Hypoxia threshold 1.045
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Figure 3 Comparison between the prediction and the observation. Top row shows the real medical
image, below the simulation. The dates are on the left 2008/09/22 (calibration) and on the right 2008/12/10
(prediction).
Figure 4 Mass evolution comparison between the data and the simulations for the tumor growth.
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Volume concordance 82.54% 77.76%
Delay (days) 0 −6.7
Normalized delay 0% −3.6%
the end of the therapy (on 2009/07/27). This last one shows a relapse as the tumor starts
growing again from the end of the treatment. It is interesting for us to calibrate the model
on this decreasing phase to try to predict the response to the treatment and possibly
the relapse. As the model has already been parametrized on the growth phase, we keep
the same parameters from this calibration and use the cytotoxic drug modeling given in
Equations 10 and 11. This second inverse problem is easier as the only parameter to esti-
mate is δ. This time again, we need two images. We use the last one before treatment (on
2008/12/10) as the initial condition and the first control (on 2009/03/21) to parametrize.
We find δ = 1.05 and then the direct model is simulated up to after the date of the last
scan (2009/07/27).
The evolution of the tumor mass during the treatment provides a good insight on the
therapeutical efficacy. It is given in Figure 5 and we can see that here again, the model is
predictive for this case and provides a good estimation of the response of the patient to
chemotherapy. The tumor shape during treatment obtained by simulation is compared to
the clinical data in Figure 6, and the shape indicators are given on Table 4.
The tumor shape is quite well reproduced by the model for the first control scan which
we use to find the treatment parameter δ. However, on the last control scan made during
the cure (on 2009/05/27), the tumor is quite hard to delineate due to various physiological
phenomena that are not taken into account in the model (such as edema or fibrosis). It
results from the cytotoxic effects of the treatment on the tumor cells. Finally, the model
Figure 5 Mass evolution comparison between the data and the simulations under treatment.
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Figure 6 Comparison between the prediction and the observation for the tumor decrease.
Comparison between the prediction and the observation for the tumor decrease due to treatment and the
relapse post treatment: above the real medical image, below the simulation. The dates are on the left
2009/03/21 (calibration) in the middle 2009/05/27 (prediction for the response to treatment) and on the
right 2009/07/27 (prediction for the relapse).
thus calibrated gives a good prediction of the relapse after the end of the chemotherapy.
For this last time point, shape comparison provides a good result.
Another clinical test case
The whole calibration method described previously was used on another case of tumor
growth. Here again, we use two scans at different time points to calibrate the model and
a third image to quantify the accuracy of the prediction. The mass comparison is given in
Figure 7.
In this case, the growth is slower than in the previous case and the model is able to
reproduce such a kind of dynamics. Indeed, the time error in prediction is about 5.6 days
which, at the time scale we work and considering the tumor registration uncertainties, is
a satisfactory result. The shape of the simulated tumor is also satisfying according to the
spatial distribution of tumor cell densities in Figure 8 and the indicators on Table 5.
Conclusion
To try to answer the questions raised by our clinical case, a new approach was developed.
First, a model was written that takes important mechanisms of tumor growth like hypoxia
Table 4 Scalar indicators for the tumor under chemotherapy and rebound of the first
clinical case: DICE, volume concordance, and delays
2009/03/21 2009/05/27 2009/07/27
DICE 92.26% 87.44% 84.79
Volume concordance 84.41% 74.56% 69.9%
Delay (days) 0.5 −0.84 −6.4
Normalized delay 0.5% −0.5% −2.8%
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Figure 7 Second test case: mass evolution comparison between the data and the simulations.
Figure 8 Comparison between the prediction and the observation for the second test case. Above the
real medical image, below the simulation. The dates are on the left 2010/03/11 (calibration) and on the right
2010/07/16 (prediction).
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Volume concordance 70.59% 76.45%
Delay (days) 0 5.6
Normalized delay 0% 2.3%
or angiogenesis into account. Yet, the model is simple enough to be calibrated for a spe-
cific patient. We have described a new calibration method based on proper orthogonal
decomposition to fit the patient data and perform a prediction of the tumor evolution;
prediction which is confirmed qualitatively and quantitatively by the medical imaging.
As the model contains various kinds of treatments, we could, on the same clinical case,
establish a precise quantitative prediction of the response to the treatment at the end of
the protocol. As shown in Figure 3, the evolution is really quick between 2008/09/22 and
2008/12/10 and is difficult to predict by the clinicians only using the scans. In that kind
of circumstances, a mathematical approach like ours could have helped the oncologist in
his diagnosis. On this particular case, the interest of the simulation is clear. For the time
being, we do not use any data on the real vasculature. With the constant progress of med-
ical imaging, one can imagine that such data will soon be available. This advancement will
validate our modeling of the vasculature M. We mainly used here two dimensional data
extracted from scans (that naturally give a 3D view of the tumor). The whole method was
coded for three-dimensional data, from the direct model simulation to the POD projec-
tion and the calibration algorithm. Currently, it is computationally too expensive to build
a database in 3D so we cannot use the whole 3D process on the clinical case. However,
by improving and making the database generation faster, it could be interesting to use a
3Dmethod as the reduced model simulation calculation time is almost the same as in 2D.
Moreover it would allow us to free ourselves from the choice of a particular slice.
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